{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:38:50Z","timestamp":1790451530226,"version":"4.1.0"},"reference-count":146,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ejso.2017.05.008","type":"journal-article","created":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T03:16:54Z","timestamp":1495077414000},"page":"1668-1681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection"],"prefix":"10.1016","volume":"43","author":[{"given":"G.","family":"Duwe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Knitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pesthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Beierle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bahra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schmelzle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.B.","family":"Schmuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lohneis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Raschzok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"\u00d6llinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Struecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.M.","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pratschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Andreou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejso.2017.05.008_bib1","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.ejso.2017.05.008_bib2","first-page":"104","article-title":"Colorectal cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.ejso.2017.05.008_bib3","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejso.2017.05.008_bib4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/bjs.5278","article-title":"A\u00a0population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer","volume":"93","author":"Leporrier","year":"2006","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.ejso.2017.05.008_bib5","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/01.sla.0000217629.94941.cf","article-title":"Epidemiology and management of liver metastases from colorectal cancer","volume":"244","author":"Manfredi","year":"2006","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ejso.2017.05.008_bib6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11605-012-2022-3","article-title":"Colorectal liver metastases","volume":"17","author":"Tzeng","year":"2013","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"8","key":"10.1016\/j.ejso.2017.05.008_bib7","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/annonc\/mdi246","article-title":"Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates","volume":"16","author":"Folprecht","year":"2005","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2017.05.008_bib8","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","article-title":"Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial","volume":"14","author":"Nordlinger","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2017.05.008_bib9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/01.sla.0000141198.92114.f6","article-title":"Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival","volume":"240","author":"Adam","year":"2004","journal-title":"Ann Surg"},{"issue":"9617","key":"10.1016\/j.ejso.2017.05.008_bib10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0140-6736(08)60455-9","article-title":"Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial","volume":"371","author":"Nordlinger","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejso.2017.05.008_bib11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdh095","article-title":"Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer","volume":"15","author":"Rubbia-Brandt","year":"2004","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.ejso.2017.05.008_bib12","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1245\/s10434-012-2438-8","article-title":"Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis","volume":"19","author":"Robinson","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2017.05.008_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.sla.0000193603.26265.c3","article-title":"Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases","volume":"243","author":"Karoui","year":"2006","journal-title":"Ann Surg"},{"issue":"13","key":"10.1016\/j.ejso.2017.05.008_bib14","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1200\/JCO.2005.05.3074","article-title":"Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases","volume":"24","author":"Vauthey","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2017.05.008_bib15","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/cncr.23099","article-title":"Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases","volume":"110","author":"Ribero","year":"2007","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ejso.2017.05.008_bib16","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study","volume":"19","author":"Hoff","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.ejso.2017.05.008_bib17","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ejso.2017.05.008_bib18","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nrclinonc.2015.129","article-title":"First-line chemotherapy for mCRC\u2014a review and evidence-based algorithm","volume":"12","author":"Cremolini","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"29","key":"10.1016\/j.ejso.2017.05.008_bib19","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1200\/JCO.2007.11.0833","article-title":"Actual 10-year survival after resection of colorectal liver metastases defines cure","volume":"25","author":"Tomlinson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2017.05.008_bib20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00000658-200206000-00002","article-title":"Trends in long-term survival following liver resection for hepatic colorectal metastases","volume":"235","author":"Choti","year":"2002","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ejso.2017.05.008_bib21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1245\/s10434-007-9607-1","article-title":"Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score","volume":"15","author":"Andres","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2017.05.008_bib22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.suc.2003.12.005","article-title":"Hepatic colorectal metastases: methods of improving resectability","volume":"84","author":"Adam","year":"2004","journal-title":"Surg Clin North Am"},{"issue":"10","key":"10.1016\/j.ejso.2017.05.008_bib23","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1245\/s10434-006-9045-5","article-title":"Improving resectability of hepatic colorectal metastases: expert consensus statement","volume":"13","author":"Abdalla","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"22","key":"10.1016\/j.ejso.2017.05.008_bib24","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1200\/JCO.2008.20.5278","article-title":"Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy","volume":"27","author":"Kopetz","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2017.05.008_bib25","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/01.sla.0000128305.90650.71","article-title":"Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection\/ablation for colorectal liver metastases","volume":"239","author":"Abdalla","year":"2004","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.ejso.2017.05.008_bib26","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1007\/s11605-007-0272-2","article-title":"Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival","volume":"11","author":"Chun","year":"2007","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"10","key":"10.1016\/j.ejso.2017.05.008_bib27","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1093\/annonc\/mds236","article-title":"ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making","volume":"23","author":"Schmoll","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2017.05.008_bib28","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1023\/A:1008347829017","article-title":"Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery","volume":"10","author":"Giacchetti","year":"1999","journal-title":"Ann Oncol"},{"issue":"29","key":"10.1016\/j.ejso.2017.05.008_bib29","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1200\/JCO.2007.10.8126","article-title":"Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy","volume":"25","author":"Adam","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2017.05.008_bib30","first-page":"265","article-title":"The management of solitary colorectal liver metastases","volume":"9","author":"Brouquet","year":"2011","journal-title":"Surgeon"},{"issue":"23","key":"10.1016\/j.ejso.2017.05.008_bib31","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ejso.2017.05.008_bib32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejso.2017.05.008_bib33","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"Andr\u00e9","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"31","key":"10.1016\/j.ejso.2017.05.008_bib34","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2006.06.8353","article-title":"Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial","volume":"24","author":"Portier","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"10.1016\/j.ejso.2017.05.008_bib35","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1200\/JCO.2008.17.3781","article-title":"Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials","volume":"26","author":"Mitry","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2017.05.008_bib36","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ctrv.2015.06.006","article-title":"Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus","volume":"41","author":"Adam","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.ejso.2017.05.008_bib37","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/bjs.5719","article-title":"Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases","volume":"94","author":"Zorzi","year":"2007","journal-title":"Br J Surg"},{"issue":"6","key":"10.1016\/j.ejso.2017.05.008_bib38","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jamcollsurg.2005.01.024","article-title":"Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases","volume":"200","author":"Fernandez","year":"2005","journal-title":"J\u00a0Am Coll Surg"},{"issue":"1","key":"10.1016\/j.ejso.2017.05.008_bib39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/SLA.0b013e31815774de","article-title":"Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy","volume":"247","author":"Nakano","year":"2008","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.ejso.2017.05.008_bib40","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1038\/bjc.1998.333","article-title":"Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer","volume":"77","author":"Peppercorn","year":"1998","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2017.05.008_bib41","first-page":"27","article-title":"Nonalcoholic fatty liver disease (NAFLD): a comprehensive review","volume":"36","author":"Salt","year":"2004","journal-title":"J\u00a0Insur Med"},{"issue":"3","key":"10.1016\/j.ejso.2017.05.008_bib42","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S1470-2045(09)70064-6","article-title":"Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases","volume":"10","author":"Chun","year":"2009","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2017.05.008_bib43","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/1097-0142(19950515)75:10<2592::AID-CNCR2820751029>3.0.CO;2-G","article-title":"Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil","volume":"75","author":"Sorensen","year":"1995","journal-title":"Cancer"},{"issue":"42","key":"10.1016\/j.ejso.2017.05.008_bib44","doi-asserted-by":"crossref","first-page":"15539","DOI":"10.3748\/wjg.v20.i42.15539","article-title":"Histopathology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Takahashi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejso.2017.05.008_bib45","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13104-015-1055-6","article-title":"Noninvasive diagnosis of chemotherapy induced liver injury by LiMAx test\u2013two case reports and a review of the literature","volume":"8","author":"Bednarsch","year":"2015","journal-title":"BMC Res Notes"},{"issue":"1","key":"10.1016\/j.ejso.2017.05.008_bib46","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","article-title":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study","volume":"140","author":"Williams","year":"2011","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ejso.2017.05.008_bib47","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1472-8206.2008.00608.x","article-title":"Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies","volume":"22","author":"Labbe","year":"2008","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ejso.2017.05.008_bib48","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.acra.2005.02.010","article-title":"Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer","volume":"12","author":"Miyake","year":"2005","journal-title":"Acad Radiol"},{"issue":"8","key":"10.1016\/j.ejso.2017.05.008_bib49","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.gassur.2003.09.012","article-title":"Impact of steatosis on perioperative outcome following hepatic resection","volume":"7","author":"Kooby","year":"2003","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"21","key":"10.1016\/j.ejso.2017.05.008_bib50","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2017.05.008_bib51","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s11605-007-0149-4","article-title":"Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome","volume":"11","author":"Pawlik","year":"2007","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"1\u20132","key":"10.1016\/j.ejso.2017.05.008_bib52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1445-2197.2011.05789.x","article-title":"The developing clinical problem of chemotherapy-induced hepatic injury","volume":"82","author":"Pilgrim","year":"2012","journal-title":"ANZ J Surg"},{"issue":"34","key":"10.1016\/j.ejso.2017.05.008_bib53","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1200\/JCO.2006.08.1828","article-title":"Chemotherapy-induced steatohepatitis in colorectal cancer patients","volume":"24","author":"Gentilucci","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2017.05.008_bib54","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00534-008-0016-z","article-title":"Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases","volume":"16","author":"Khan","year":"2009","journal-title":"J\u00a0Hepatobiliary Pancreat Surg"},{"issue":"4","key":"10.1016\/j.ejso.2017.05.008_bib55","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"issue":"5069","key":"10.1016\/j.ejso.2017.05.008_bib56","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(01)00020-4","article-title":"Originally published as volume 2, issue 5069 senecio disease, or cirrhosis of the liver due to senecio poisoning","volume":"196","author":"Willmot","year":"1920","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejso.2017.05.008_bib57","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment","volume":"22","author":"Dalle","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"10.1016\/j.ejso.2017.05.008_bib58","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/hep.510290615","article-title":"Characterization of a reproducible rat model of hepatic veno-occlusive disease","volume":"29","author":"DeLeve","year":"1999","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ejso.2017.05.008_bib59","doi-asserted-by":"crossref","first-page":"G1045","DOI":"10.1152\/ajpgi.00526.2002","article-title":"Embolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome","volume":"284","author":"DeLeve","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"4","key":"10.1016\/j.ejso.2017.05.008_bib60","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/hep.1840380416","article-title":"Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome","volume":"38","author":"DeLeve","year":"2003","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ejso.2017.05.008_bib61","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0016-5085(03)01056-4","article-title":"Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition","volume":"125","author":"DeLeve","year":"2003","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.ejso.2017.05.008_bib62","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/hep.510230326","article-title":"Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease","volume":"23","author":"DeLeve","year":"1996","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ejso.2017.05.008_bib63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2036.2006.02742.x","article-title":"Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome","volume":"23","author":"Helmy","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.ejso.2017.05.008_bib64","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2012.07.004","article-title":"Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9","volume":"57","author":"Nakamura","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.ejso.2017.05.008_bib65","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jhep.2013.04.014","article-title":"Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model","volume":"59","author":"Robinson","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.ejso.2017.05.008_bib66","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/sj.bmt.1703061","article-title":"Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation","volume":"27","author":"Iguchi","year":"2001","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"10.1016\/j.ejso.2017.05.008_bib67","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.critrevonc.2013.05.011","article-title":"Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: a review of mechanisms and outcomes","volume":"88","author":"McWhirter","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.ejso.2017.05.008_bib68","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1535-7163.MCT-10-1072","article-title":"Gene expression profiling provides insights into pathways of oxaliplatin-related sinusoidal obstruction syndrome in humans","volume":"10","author":"Rubbia-Brandt","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.ejso.2017.05.008_bib69","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jhep.2011.10.023","article-title":"Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation","volume":"56","author":"Agostini","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.ejso.2017.05.008_bib70","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.surg.2008.12.002","article-title":"Risk factors for chemotherapy-associated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases","volume":"145","author":"Brouquet","year":"2009","journal-title":"Surgery"},{"issue":"3","key":"10.1016\/j.ejso.2017.05.008_bib71","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3892\/mco.2015.512","article-title":"Oxaliplatin-based chemotherapy induces extravasated platelet aggregation in the liver","volume":"3","author":"Tajima","year":"2015","journal-title":"Mol Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2017.05.008_bib72","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1365-2559.2010.03511.x","article-title":"Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis","volume":"56","author":"Rubbia-Brandt","year":"2010","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.ejso.2017.05.008_bib73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2002-23204","article-title":"Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease)","volume":"22","author":"DeLeve","year":"2002","journal-title":"Semin Liver Dis"},{"issue":"31","key":"10.1016\/j.ejso.2017.05.008_bib74","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1200\/JCO.2006.05.8156","article-title":"Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases","volume":"24","author":"Aloia","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2017.05.008_bib75","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/SLA.0b013e3181c79403","article-title":"Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome","volume":"251","author":"Soubrane","year":"2010","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.ejso.2017.05.008_bib76","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1245\/s10434-010-1317-4","article-title":"Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy","volume":"18","author":"Tamandl","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2017.05.008_bib77","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2559.2012.04208.x","article-title":"Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases","volume":"61","author":"Vreuls","year":"2012","journal-title":"Histopathology"},{"issue":"11","key":"10.1016\/j.ejso.2017.05.008_bib78","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1245\/s10434-010-1166-1","article-title":"Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases","volume":"17","author":"Kishi","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2017.05.008_bib79","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/sj.bjc.6603670","article-title":"Safe liver resection following chemotherapy for colorectal metastases is a matter of timing","volume":"96","author":"Welsh","year":"2007","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.ejso.2017.05.008_bib80","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.2007.13.7679","article-title":"Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer","volume":"26","author":"Gruenberger","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2017.05.008_bib81","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/s-2008-1076681","article-title":"Standardized liver volumetry for portal vein embolization","volume":"25","author":"Ribero","year":"2008","journal-title":"Semin Interv Radiol"},{"issue":"4","key":"10.1016\/j.ejso.2017.05.008_bib82","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/SLA.0b013e3181b674df","article-title":"Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry","volume":"250","author":"Kishi","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2017.05.008_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2017.01.031","article-title":"Hepatic atrophy following preoperative chemotherapy predicts hepatic insufficiency after resection of colorectal liver metastases","author":"Yamashita","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.ejso.2017.05.008_bib84","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/SLA.0b013e31815f6e5b","article-title":"Preoperative portal vein embolization for major liver resection: a meta-analysis","volume":"247","author":"Abulkhir","year":"2008","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.ejso.2017.05.008_bib85","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.surg.2014.12.009","article-title":"A\u00a0systematic review and meta-analysis of portal vein ligation versus portal vein embolization for elective liver resection","volume":"157","author":"Pandanaboyana","year":"2015","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.ejso.2017.05.008_bib86","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jamcollsurg.2012.10.018","article-title":"Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant","volume":"216","author":"Shindoh","year":"2013","journal-title":"J\u00a0Am Coll Surg"},{"issue":"4","key":"10.1016\/j.ejso.2017.05.008_bib87","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/jso.24139","article-title":"Neoadjuvant chemotherapy does not impair liver regeneration following hepatectomy or portal vein embolization for colorectal cancer liver metastases","volume":"113","author":"Simoneau","year":"2016","journal-title":"J\u00a0Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2017.05.008_bib88","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/SLA.0b013e31815ed693","article-title":"Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases","volume":"247","author":"Covey","year":"2008","journal-title":"Ann Surg"},{"issue":"12","key":"10.1016\/j.ejso.2017.05.008_bib89","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamasurg.2013.2126","article-title":"Chemotherapy after portal vein embolization to protect against tumor growth during liver hypertrophy before hepatectomy","volume":"148","author":"Fischer","year":"2013","journal-title":"JAMA Surg"},{"issue":"23","key":"10.1016\/j.ejso.2017.05.008_bib90","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ejso.2017.05.008_bib91","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(09)70330-4","article-title":"Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial","volume":"11","author":"Folprecht","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2017.05.008_bib92","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12885-016-2095-6","article-title":"Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases","volume":"16","author":"Volk","year":"2015","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2017.05.008_bib93","first-page":"15","article-title":"Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection","volume":"12","author":"Constantinidou","year":"2013","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2017.05.008_bib94","first-page":"38","article-title":"Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study","volume":"11","author":"Bennouna","year":"2012","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"10.1016\/j.ejso.2017.05.008_bib95","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ejso.2017.05.008_bib96","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ejso.2017.05.008_bib97","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"Bokemeyer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejso.2017.05.008_bib98","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ejso.2017.05.008_bib99","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/nrclinonc.2013.93","article-title":"Surgery: cetuximab\u2013an option for unresectable CRC liver metastases","volume":"10","author":"Laurent-Puig","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.ejso.2017.05.008_bib100","doi-asserted-by":"crossref","first-page":"a3576","DOI":"10.1200\/jco.2011.29.15_suppl.3576","article-title":"Efficacy of chemotherapy plus cetuximab according to metastatic site in KRAS wild-type metastatic colorectal cancer (mCRC): analysis of CRYSTAL and OPUS studies [abstract]","volume":"29","author":"Koehne","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2017.05.008_bib101","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","article-title":"Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study","volume":"22","author":"Bokemeyer","year":"2011","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.ejso.2017.05.008_bib102","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.ejso.2017.05.008_bib103","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1200\/JCO.2012.44.8308","article-title":"Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases","volume":"31","author":"Ye","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"9783","key":"10.1016\/j.ejso.2017.05.008_bib104","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(11)60613-2","article-title":"Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"377","author":"Maughan","year":"2011","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ejso.2017.05.008_bib105","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1200\/JCO.2011.38.0915","article-title":"Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study","volume":"30","author":"Tveit","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2017.05.008_bib106","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1470-2045(14)70105-6","article-title":"Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial","volume":"15","author":"Primrose","year":"2014","journal-title":"Lancet Oncol"},{"issue":"31","key":"10.1016\/j.ejso.2017.05.008_bib107","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2017.05.008_bib108","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ejso.2017.05.008_bib109","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00432-011-1061-6","article-title":"First-line panitumumab plus irinotecan\/5-fluorouracil\/leucovorin treatment in patients with metastatic colorectal cancer","volume":"138","author":"K\u00f6hne","year":"2012","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejso.2017.05.008_bib110","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1002\/cncr.28223","article-title":"Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study","volume":"119","author":"Leone","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2017.05.008_bib111","article-title":"Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials","author":"Tejpar","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejso.2017.05.008_bib112","article-title":"Prognostic impact of primary tumor location on clinical outcomes of metastatic colorectal cancer treated with cetuximab plus oxaliplatin-based chemotherapy: a subgroup analysis of the JACCRO CC-05\/06 trials","author":"Sunakawa","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ejso.2017.05.008_bib113","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","article-title":"The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials","volume":"70","author":"Holch","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2017.05.008_bib114","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2017.05.008_bib115","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2017.05.008_bib116","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2017.05.008_bib117","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1470-2045(10)70175-3","article-title":"Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial","volume":"11","author":"Masi","year":"2010","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2017.05.008_bib118","doi-asserted-by":"crossref","first-page":"e0161912","DOI":"10.1371\/journal.pone.0161912","article-title":"Bevacizumab combined with chemotherapy improves survival for patients with metastatic colorectal cancer: evidence from meta analysis","volume":"11","author":"Ilic","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ejso.2017.05.008_bib119","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/bjc.2013.140","article-title":"Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial","volume":"108","author":"Nasti","year":"2013","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ejso.2017.05.008_bib120","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s12253-013-9608-2","article-title":"Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment","volume":"19","author":"Dede","year":"2013","journal-title":"Pathol Oncol Res"},{"issue":"9617","key":"10.1016\/j.ejso.2017.05.008_bib121","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(08)60429-8","article-title":"Perioperative chemotherapy for resectable hepatic metastases","volume":"371","author":"Kopetz","year":"2008","journal-title":"Lancet"},{"issue":"36","key":"10.1016\/j.ejso.2017.05.008_bib122","doi-asserted-by":"crossref","first-page":"9243","DOI":"10.1200\/JCO.2005.07.740","article-title":"Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study","volume":"23","author":"Alberts","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejso.2017.05.008_bib123","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"Falcone","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2017.05.008_bib124","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1245\/ASO.2006.03.094","article-title":"Treatment with 5-fluorouracil\/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer","volume":"13","author":"Masi","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2017.05.008_bib125","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/annonc\/mdh217","article-title":"Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients","volume":"15","author":"Pozzo","year":"2004","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2017.05.008_bib126","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10147-012-0382-z","article-title":"Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study","volume":"18","author":"Takahashi","year":"2013","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2017.05.008_bib127","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/bjc.2011.43","article-title":"FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer","volume":"104","author":"Bertolini","year":"2011","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ejso.2017.05.008_bib128","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1245\/s10434-014-4094-7","article-title":"A\u00a0multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808)","volume":"22","author":"Uetake","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2017.05.008_bib129","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1093\/annonc\/mdq714","article-title":"A\u00a0multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection","volume":"22","author":"Wong","year":"2011","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2017.05.008_bib130","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/annonc\/mdl386","article-title":"Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery","volume":"18","author":"Rubbia-Brandt","year":"2007","journal-title":"Ann Oncol"},{"issue":"33","key":"10.1016\/j.ejso.2017.05.008_bib131","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1200\/JCO.2008.17.5299","article-title":"Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases","volume":"26","author":"Blazer","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2017.05.008_bib132","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2007.13.7471","article-title":"Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality?","volume":"26","author":"Adam","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2017.05.008_bib133","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1245\/s10434-010-0972-9","article-title":"Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX\/FOLFOX","volume":"17","author":"Klinger","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2017.05.008_bib134","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ejso.2017.05.008_bib135","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1200\/JCO.2007.13.3652","article-title":"Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan","volume":"26","author":"Sathornsumetee","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2017.05.008_bib136","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1200\/JCO.2007.13.8099","article-title":"Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107","volume":"26","author":"Grothey","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejso.2017.05.008_bib137","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria","volume":"25","author":"Choi","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.ejso.2017.05.008_bib138","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1001\/jama.2009.1755","article-title":"Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases","volume":"302","author":"Chun","year":"2009","journal-title":"Jama"},{"issue":"36","key":"10.1016\/j.ejso.2017.05.008_bib139","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1200\/JCO.2012.45.2854","article-title":"Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases","volume":"30","author":"Shindoh","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2017.05.008_bib140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000356218","article-title":"Predictive value of optimal morphologic response to first-line chemotherapy in patients with colorectal liver metastases","volume":"89","author":"Yoshita","year":"2014","journal-title":"Digestion"},{"issue":"9","key":"10.1016\/j.ejso.2017.05.008_bib141","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s11605-015-2836-x","article-title":"Radiological morphology of colorectal liver metastases after preoperative chemotherapy predicts tumor viability and postoperative outcomes","volume":"19","author":"Nishioka","year":"2015","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"2","key":"10.1016\/j.ejso.2017.05.008_bib142","first-page":"198","article-title":"Non-size-based response criteria to preoperative chemotherapy in patients with colorectal liver metastases: the morphologic response criteria","volume":"9","author":"Shindoh","year":"2013","journal-title":"Curr Colorectal Cancer Rep"},{"issue":"5","key":"10.1016\/j.ejso.2017.05.008_bib143","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ejso.2008.12.013","article-title":"Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX\/FOLFOX therapy of colorectal cancer liver metastases","volume":"35","author":"Klinger","year":"2009","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2017.05.008_bib144","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/SLA.0b013e31827381ca","article-title":"Volumetric analysis of remnant liver regeneration after major hepatectomy in bevacizumab-treated patients: a case-matched study in 82 patients","volume":"256","author":"Millet","year":"2012","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.ejso.2017.05.008_bib145","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1152\/physrev.00027.2008","article-title":"The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair","volume":"89","author":"Vollmar","year":"2009","journal-title":"Physiol Rev"},{"issue":"4","key":"10.1016\/j.ejso.2017.05.008_bib146","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1083\/jcb.140.4.947","article-title":"Vascular endothelial growth factor induces endothelial fenestrations in\u00a0vitro","volume":"140","author":"Esser","year":"1998","journal-title":"J\u00a0Cell Biol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798317304869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798317304869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:24:30Z","timestamp":1760059470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798317304869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":146,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0748798317304869"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2017.05.008","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2017.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}